Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.

Blood - 28 Jan 2021

Zhao Yaqi, Aldoss Ibrahim, Qu Chunxu, Crawford Jeremy Chase, Gu Zhaohui, Allen Emma K, Zamora Anthony E, Alexander Thomas B, Wang Jeremy, Goto Hiroaki, Imamura Toshihiko, Akahane Koshi, Marcucci Guido, Stein Anthony S, Bhatia Ravi, Thomas Paul G, Forman Stephen J, Mullighan Charles G, Roberts Kathryn G

Abstract excerpt

Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and -extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including 2 minimal residual disease positive) treated with blinatumomab using bulk tumor and single-cell sequencing. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aneuploidy
Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD19

Share to Antineoplastic Agents, Immunological

Share to Cytotoxicity, Immunologic

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to RNA, Neoplasm

Share to Salvage Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 32881995
DOI: 10.1182/blood.2020006287
PMCID: PMC7845009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.PMID 32881995Read ↗

Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapySemantic proximity Read ↗

Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantationSemantic proximity Read ↗

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemiaSemantic proximity Read ↗

Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL.Semantic proximity Read ↗

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaSemantic proximity Read ↗

Multi-courses of Blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo intolerant middle to high-risk pediatric B-ALL patients with invasive fungal diseaseSemantic proximity Read ↗

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy eraSemantic proximity Read ↗

Molecular signature of pediatric B-ALL determines outcomes post CD19 CAR-T cell therapySemantic proximity Read ↗

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.